Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239679 · ClinicalTrials.gov registry record · Phase 2
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
A Phase 2 study, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT02239679 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 166 participants.
The verdict
NCT02239679, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Levulan photodynamic therapy (PDT) is safe and effective in the treatment of actinic keratoses (AK) on the face, following treatment with liquid nitrogen cryotherapy.
Interventions
- PROCEDURE Cryotherapy
- DEVICE BLU-U
- DRUG Aminolevulinic Acid
- DRUG Topical Solution Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02239679
The ClinicalTrials.gov registry entry for NCT02239679 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cryotherapy is the first listed.
NCT02239679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02239679 about?
NCT02239679 is a clinical study titled "Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy". The purpose of this study is to determine if Levulan photodynamic therapy (PDT) is safe and effective in the treatment of actinic keratoses (AK) on the face, following treatment with liquid nitrogen cryotherapy.
What is the current status of trial NCT02239679?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2014-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02239679?
The interventions under investigation include: Cryotherapy (PROCEDURE), BLU-U (DEVICE), Aminolevulinic Acid (DRUG), Topical Solution Vehicle (DRUG).
Who is sponsoring clinical trial NCT02239679?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.